Insulin resistance and lipid profile in women with polycystic appearing ovaries: Implications with regard to polycystic ovary syndrome

Gynecological Endocrinology

Volumn 17, Issue 5, 2003, Pages 387-396

  Sayin, N Cenk ^a   Gucer F ^a   Balkanli Kaplan, P ^a   Yüce, M Ali ^a   Yardim, T ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Androgen; Insulin; Lipid; Polycystic Ovary Syndrome

Indexed keywords

ANDROGEN; CHOLESTEROL; ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY DISEASE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; TRANSVAGINAL ECHOGRAPHY;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; TRIGLYCERIDES;

EID: 0242301686     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590312331290278     Document Type: Article

References (46)

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800
2. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, et al., eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific Publications, 1992:377-84
3. Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril 1999;71:319-22
4. Oberfield SE. Metabolic lessons from the study of young adolescents with polycystic ovary syndrome - is insulin indeed, the culprit? (editorial) J Clin Endocrinol Metab 2000;85:3520-5
5. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;3:853-61
6. Rajkhowa M, Glass MR, Rutherford AJ, et al. Polycystic ovary syndrome: a risk factor for cardiovascular disease. Br J Obstet Gynaecol 2000;107:11-18
7. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50: 113-16
8. Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38: 1165-74
9. Chang RJ, Nakamura RM, Judd HL, et al. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983;57: 356-9
10. Dunaif A, Graf M, Mandeli J, et al. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia. J Clin Endocrinol Metab 1987;65:499-507
11. Conway GS, Agrawal R, Betteridge DJ, et al. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;37:119-25
12. Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000;15:1266-74
13. Kelly CJG, Connell JMC, Cameron IT, et al. The long-term health consequences of polycystic ovary syndrome. Br J Obstet Gynaecol 2000;107:1327-38
14. Rajkhowa M, Neary RH, Kumpatla P, et al. Altered composition of high-density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:3389-94
15. Wild RA, Painter PC, Coulson PB, et al. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-51
16. Loucks TL, Talbott EO, McHugh KP, et al. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome? Fertil Steril 2000;74:547-52
17. Gupta S. Polycystic ovarian syndrome: is community care appropriate? Int J Clin Pract 1999;53:359-62
18. Holte J, Bergh T, Berne C, et al. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 1994; 41:463-71
19. Graf MJ, Richards CJ, Brown V, et al. The independent effects ofhyperandrogenaemia, hyperinsulinaemia and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol (Oxf) 1990;33:119-31
20. Slowinska-Srzednicka J, Zgliczynski S, Wierzbicki M, et al. The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. J Endocrinol Invest 1991;14:569-75
21. Gennarelli G, Holte J, Berglund L, et al. Prediction models for insulin resistance in the polycystic ovary syndrome. Hum Reprod 2000;15:2098-102
22. Talbott EO, Zborowski JV, Sutton-Tyrell K, et al. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28:111-33
23. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989-93
24. Carmina E, Wong L, Chang L, et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 1997;12:905-9
25. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986;293:355-9
26. Katz A, Nambi SS, Mather K, et al. Quantitative Insulin Sensitivity Check Index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10
27. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000;23:57-63
28. Koivunen R, Laatikainen T, Tomas C, et al. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Stand 1999;78:137-41
29. Polson DW, Wadsworth J, Adams J, et al. Polycystic ovaries - common finding in normal women. Lancet 1988;1:870-2
30. Norman RJ, Hague WM, Masters SC, et al. Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. Hum Reprod 1995;10:2258-61
31. Van Santbrink EJP, Hop WC, Fauser BCJM. Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril 1997;67:452-8
32. Pirwany IR, Fleming R, Greer IA, et al. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001;54:447-53
33. Velazquez ME, Bellabarba GA, Mendoza S, et al. Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin. Fertil Steril 2000;74:1159-63
34. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925-9
35. Yip J, Facchini F, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998; 88:2773-6
36. Rajkhowa M, Bicknell J, Jones M, et al. Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia. Fertil Steril 1994;61:605-12
37. Arthur LSC, Selvakumar R, Seshadri M, et al. Hyperinsulinemia in polycystic ovary disease. J Reprod Med 1999;44:783-7
38. Haffner SM, Katz MS, Stern MP, et al. The relationship of sex hormones to hyperinsulinemia and hyperglycemia. Metabolism 1988;37:683-8
39. Acien P, Quereda F, Matallin P, et al. Insulin, androgens and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999;72:32-40
40. Anttila L, Ding Y-Q, Ruutiainen K, et al. Clinical features and circulating gonadotropin, insulin and androgen interactions in women with polycystic ovarian disease. Fertil Steril 1991;55:1057-61
41. Sampson M, Kong C, Patel A, et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996;45:623-9
42. Hopkinson ZEC, Sattar N, Fleming R, et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. Br Med J 1998;317:329-32
43. Jensen J. Effects of sex steroids on serum lipids and lipoproteins. Bailliere's Clin Obstet Gynecol 1991; 5:867-87
44. Mahabeer S, Naidoo C, Norman RJ, et al. Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease. Horm Metab Res 1990;22:537-40
45. Frayn KN. Insulin resistance and lipid metabolism. Curr Opin Lipidol 1993;4:197-204
46. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410-15